Media coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.9056537716995 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Carl Domino Inc Buys DowDuPont Inc, Bank of America Corporation, CenturyLink Inc, Sells Paychex … (nasdaq.com)
- Should You Worry About Amyris Inc’s (AMRS) CEO Pay? (finance.yahoo.com)
- Amyris Reschedules Third Quarter 2017 Financial Results Teleconference for Tuesday, November 14, 2017 – GlobeNewswire (press release) (globenewswire.com)
Amyris (AMRS) opened at $3.17 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.65 and a debt-to-equity ratio of -0.76. Amyris has a 1 year low of $1.86 and a 1 year high of $14.85.
A number of brokerages have issued reports on AMRS. Zacks Investment Research upgraded Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright set a $15.00 price target on Amyris and gave the stock a “buy” rating in a research report on Friday, August 11th. Cowen and Company set a $4.00 price target on Amyris and gave the stock a “hold” rating in a research report on Thursday, August 17th. Finally, ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Amyris currently has a consensus rating of “Hold” and a consensus target price of $20.69.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.